<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281983</url>
  </required_header>
  <id_info>
    <org_study_id>CLL3X</org_study_id>
    <secondary_id>EU-20554</secondary_id>
    <secondary_id>MEDAC-FLUD.10/CLL</secondary_id>
    <nct_id>NCT00281983</nct_id>
  </id_info>
  <brief_title>Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia</brief_title>
  <official_title>Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German CLL Study Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of
      cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem
      cells. Also, monoclonal antibodies, such as alemtuzumab, can find cancer cells and either
      kill them or deliver cancer-killing substances to them without harming normal cells. When the
      healthy stem cells from a donor are infused into the patient they may help the patient's bone
      marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
      transplanted cells from a donor can make an immune response against the body's normal cells.
      Giving methotrexate, cyclosporine and mycophenolate mofetil after the transplant may stop
      this from happening. Once the donated stem cells begin working, the patient's immune system
      may see the remaining cancer cells as not belonging in the patient's body and destroy them
      (called graft-versus-tumor effect). Giving an infusion of the donor's white blood cells
      (donor lymphocyte infusion) may boost this effect.

      PURPOSE: This phase I/II trial is studying the side effects of giving fludarabine together
      with cyclophosphamide and to see how well they work in treating patients who are undergoing
      donor stem cell transplant for B-cell chronic lymphocytic leukemia or Waldenstr√∂m's
      macroglobulinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility and safety of induction therapy comprising fludarabine and
           cyclophosphamide followed by allogeneic stem cell transplantation in patients with
           high-risk B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma
           (Waldenstrom's macroglobulinemia).

      Secondary

        -  Determine the incidence and kinetics of clinical and molecular remissions in patients
           treated with this regimen.

        -  Determine event-free and overall survival of patients treated with this regimen.

        -  Determine the duration of clinical and molecular remission in relation to the underlying
           cytogenetic deviation in patients treated with this regimen.

        -  Determine the kinetics and extent of lympho-hematopoietic donor chimerism in patients
           treated with this regimen.

      OUTLINE: This is a multicenter, open-label, nonrandomized, pilot study.

        -  Cytoreductive therapy: Patients receive up to 3 courses of cytoreductive therapy
           comprising fludarabine IV and cyclophosphamide IV on days 1-3 (with or without rituximab
           IV on day 1). Patients refractory to fludarabine-containing therapy may receive
           alemtuzumab IV for 12 weeks OR any other cytotoxic salvage regimen for cytoreduction.

        -  Conditioning regimen: Patients receive 1 of the following conditioning regimens*:

      NOTE: *Patients who did not achieve partial response after cytoreductive therapy receive
      regimen 3.

        -  Regimen 1: Patients receive fludarabine IV and cyclophosphamide IV on days -7 to -3. If
           stem cells are collected from an unrelated donor, patients also receive anti-thymocyte
           globulin (ATG) IV on days -4 to -1.

        -  Regimen 2: Patients undergo total-body irradiation on day -9. Patients then receive
           alemtuzumab IV on days -8 to -4 and fludarabine IV and cyclophosphamide IV on days -6 to
           -2.

        -  Regimen 3: Patients receive fludarabine IV on days -7 to -3, busulfan IV or orally on
           days -7 to -5, and cyclophosphamide IV on days -3 to -2. If stem cells are collected
           from an unrelated donor, patients also receive ATG on days -3 to -1.

             -  Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo
                allogeneic PBSCT on day 0. Patients receive filgrastim (G-CSF) subcutaneously daily
                starting on day 5 and continuing until blood count recover.

             -  Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV
                beginning on day -1 and continuing until approximately day 100. Patients treated
                with conditioning regimen 1 or 3 also receive methotrexate IV on days 1, 3, and 6
                OR oral mycophenolate mofetil twice daily on days 0-50. Patients with evidence of
                residual disease at least 4 weeks after completion of cyclosporine undergo donor
                lymphocyte infusion (DLI).

             -  DLI: The donor T-lymphocytes are collected from the PBSCT donor without prior G-CSF
                mobilization. Patients receive DLI every 8 weeks in the presence of residual
                disease and the absence of GVHD.

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility as measured by the proportion of eligible patients completing the transplant procedure successfully</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by a treatment-related mortality of &lt; 25% at 2 years following transplant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission rate by NIH criteria at 12 months following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease negativity rate as measured by high-resolution flow or CDR PCR at 12 months following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism as measured by STR-PCR at 12 months following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free and overall survival at 5 years following transplant</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoreductive therapy for inducing a state of partial remission:
FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)
Conditioning regimen:
FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)
allogeneic-PBSCT (from HLA-identical donor)
GVHD prophylaxis: CSA + MTX or MMF
+/- DLI (Donor lymphocyte infusions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Allogeneic stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma
             (Waldenstrom's macroglobulinemia)

               -  Must have poor prognostic features and low probability of successful
                  autografting, defined by one of the following criteria:

                    -  Progressive disease with unfavorable cytogenetics (deletion or mutation of
                       critical regions on chromosomes 11q and/or 17p [p53]; and/or unmutated
                       status of the immunoglobulin V_H gene region; and/or usage of the V_H 3-21
                       gene), defined as 1 of the following:

                         -  Doubling of lymphocyte count or nodal involvement within 3 months or
                            less

                         -  Progressive decline of platelet count and/or hemoglobin values defining
                            Binet stage C disease (or to 50% or less of baseline values within 3
                            months) not due to immune mechanisms

                         -  Symptomatic splenomegaly

                         -  Discomfort or imminent complications due to large tumor masses

                         -  B symptoms

                    -  Refractory disease or early relapse (within 12 months) after treatment with
                       a fludarabine-containing regimen

                    -  Relapsed after autologous stem cell transplant (SCT)

                    -  Insufficient stem cell harvest for intended autologous SCT

          -  Presence of a clonal CDR III rearrangement detected by polymerase chain reaction

          -  No Richter's syndrome

          -  HLA-identical sibling or unrelated donor available

        PATIENT CHARACTERISTICS:

          -  ECOG performance status ‚â§ 1

          -  Creatinine clearance &gt; 60 mL/min

          -  SGOT, SGPT, and bilirubin &lt; 2 times normal

          -  Normal cardiac function determined by ECG and echocardiographic examination

          -  Inspiratory vital capacity, FEV_1, and DLCO &gt; 50% of predicted

          -  No serious localized or systemic infections

          -  No other concurrent malignant disease

          -  No impaired organ function

          -  No uncontrolled diabetes

          -  No uncontrolled hypertension

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No HIV infection

          -  No hepatitis B or C infection

          -  No concurrent alcohol or drug abuse

          -  No dementia or altered mental status that would preclude giving informed consent

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Dreger</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaets-Kinderklinik Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Kinderklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dcllsg.de/en/trial/cll3x/index.php</url>
    <description>Click here for more information about this study: CLL3X (German CLL Study Group)</description>
  </link>
  <results_reference>
    <citation>Dreger P, D√∂hner H, Ritgen M, B√∂ttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. doi: 10.1182/blood-2010-03-275420. Epub 2010 Jul 1.</citation>
    <PMID>20595516</PMID>
  </results_reference>
  <results_reference>
    <citation>Ritgen M, B√∂ttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, D√∂hner H, Dreger P; German CLL Study Group. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia. 2008 Jul;22(7):1377-86. doi: 10.1038/leu.2008.96. Epub 2008 Apr 17.</citation>
    <PMID>18418404</PMID>
  </results_reference>
  <results_reference>
    <citation>Dreger P, Schnaiter A, Zenz T, B√∂ttcher S, Rossi M, Paschka P, B√ºhler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, D√∂hner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. doi: 10.1182/blood-2012-11-469627. Epub 2013 Feb 22.</citation>
    <PMID>23435461</PMID>
  </results_reference>
  <results_reference>
    <citation>Scheffold A, Jebaraj BMC, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, B√∂ttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, D√∂hner H, Dreger P, Stilgenbauer S. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. Br J Haematol. 2017 Oct;179(2):342-346. doi: 10.1111/bjh.14219. Epub 2016 Jul 8.</citation>
    <PMID>27391907</PMID>
  </results_reference>
  <results_reference>
    <citation>Kr√§mer I, Stilgenbauer S, Dietrich S, B√∂ttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, D√∂hner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. doi: 10.1182/blood-2017-04-775841. Epub 2017 Jul 17.</citation>
    <PMID>28716861</PMID>
  </results_reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

